Moderna will pay up to $2.25B to end COVID vaccine patent fight

Moderna agreed to pay Genevant (Roivant subsidiary) and Arbutus up to $2.25 billion to settle long-running litigation over lipid nanoparticle (LNP) technology, with $950 million due upfront in July 2026 and $1.3 billion contingent on the outcome of a separate appeal. The deal resolves U.S. and international suits, removes the risk of potential double-digit royalties and bars royalties on LNP for Moderna’s future vaccines, a material de-risking given roughly $48 billion of past global vaccine sales. Shares reacted strongly (Moderna +10% after-hours; Arbutus +11%; Roivant +1%), and analysts noted the settlement eliminates major downside royalty scenarios that could have affected upcoming COVID and combo vaccine economics.

Analysis

Market structure: Moderna (MRNA) is the primary beneficiary — a $950m upfront + up to $2.25bn cap equals ≈4.7% of its historical ~$48bn COVID sales and removes upside royalty tail that could have been double-digit percent on future COVID/combination vaccine revenues. Arbutus (ABUS) and Genevant/Roivant (ABUS/ROIV) capture a cash infusion and optionality (balance-sheet repair/licensing), but their market moves price in contingent risk because ~58% of the headline payment is appeal-dependent. Pfizer/BioNTech (PFE/BNTX) lose relative positioning: they still face active LNP claims, so competitive pricing and margin dynamics in the COVID vaccine oligopoly change in Moderna’s favor.

Risk assessment: Immediate (days) volatility should compress for MRNA; short-term (weeks–months) risks center on the appellate outcome that triggers the $1.3bn and on BioNTech’s countersuit over MNEXSPIKE; long-term (2026–2028) risks include follow-on suits (GSK, Alnylam) and any successful challenges that could force cross-licensing. Tail risks: an adverse appellate ruling, a surprise injunction, or governments pursuing compulsory licensing would be high-impact but low-probability; hidden dependency: the deal likely contains IP carve-outs that could still expose Moderna to narrower injunctions or licensing demands for combo products.

Trade implications: Take modest, time-boxed exposure: buy MRNA equity exposure sized 1.5–2% of fund AUM, scaling into position over 2–6 weeks post-announcement and target selling 50% on +30% and stop at -12%; complement with a directional call spread (expiry ~Aug–Oct 2026) to lever upside around the July 2026 payment while capping premium. Allocate 0.5–1% long ABUS to capture windfall re-rating but plan to exit upon cash receipt (July–Sep 2026) because upside is largely binary; consider a pair trade long MRNA / short PFE (ratio 0.8:1) over 3–6 months to express differentiated IP risk.

Key Decisions for Investors

• Establish a 1.5–2.0% long position in MRNA within 2 weeks; use a stop-loss at -12% and trim 50% at +30%; horizon: hold to at least July–Aug 2026 (payment window) to capture removal of royalty overhang.
• Buy an MRNA call spread (bull call spread) expiring Aug–Oct 2026: buy near-the-money call / sell ~1.2x strike to finance premium, size to target 2:1 delta exposure relative to equity position; rationale: asymmetric upside around the July 2026 cash payment while capping downside.
• Open 0.5–1.0% long in ABUS immediately to capture settlement rerating but plan to exit 50–100% of the position upon the July–Sep 2026 cash receipt; downside: contingent $1.3bn makes value binary.
• Implement a relative-value pair: long MRNA / short PFE (ratio ~0.8:1) sized to be market-neutral sector exposure for 3–6 months; exit if PFE or BNTX see definitive favorable ruling for plaintiffs or if MRNA drops >15% from entry.
• Monitor three binary catalysts over the next 6–12 months and act: (1) appellate decision triggering $1.3bn (by mid/late 2026), (2) Delaware/Pfizer-BioNTech trial milestones (next 3–9 months), (3) FDA filings/clearance or commercial guidance for MNEXSPIKE or COVID/flu combo (next 6–12 months); only increase risk-size after clearance of at least two catalysts.